Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Bioniz	Common Stock	Common Stock Bioniz	Additional Paid-in Capital	Additional Paid-in Capital Bioniz	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2021	$ 66,505		$ 2		$ 176,618		$ (138)	$ (109,977)
Balance, Shares at Dec. 31, 2021			29,455,668
Issuance of common stock		$ 22,542		$ 1		$ 22,541
Issuance of common stock, Shares				4,820,230
Issuance of common stock under employee stock purchase plan	215				215
Issuance of common stock under employee stock purchase plan, Shares			138,251
Vesting of restricted stock liability	53				53
Stock-based compensation expense	4,841				4,841
Comprehensive income	214						214
Net loss	(62,428)							(62,428)
Balance at Dec. 31, 2022	31,942		$ 3		204,268		76	(172,405)
Balance, Share at Dec. 31, 2022			34,414,149
Issuance of common stock, Shares				849,133
Issuance of common stock under employee stock purchase plan	165				165
Issuance of common stock under employee stock purchase plan, Shares			289,855
Common stock repurchased	(260)		$ (300)		(260)
Common stock repurchased, Shares			(298,385)
Stock-based compensation expense	3,997				3,997
Comprehensive income	64						64
Net loss	(13,335)							(13,335)
Balance at Dec. 31, 2023	$ 22,573		$ 3		$ 208,170		$ 140	$ (185,740)
Balance, Share at Dec. 31, 2023			35,254,752